Monoclonal antibody LYM-1-I-131

Drug Profile

Monoclonal antibody LYM-1-I-131

Alternative Names: LYM-1-I-131; Oncolym

Latest Information Update: 18 Dec 2007

Price : $50

At a glance

  • Originator Northwestern University
  • Developer Peregrine Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Aug 2003 LYM-1-I-131 is available for licensing
  • 19 Jun 2001 Peregrine reacquires the worldwide commercialisation rights to LYM-1-I-131 from Schering AG
  • 27 Nov 2000 Techniclone Corporation is now called Peregrine Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top